共 101 条
[1]
Boyle P(2012)Triple-negative breast cancer: epidemiological considerations and recommendations Ann Oncol Supl 6 vi7-vi12
[2]
Lee FY(2009)Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemother Pharmocol 63 201-212
[3]
Smykla R(2001)BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 1429-1437
[4]
Johnston K(2007)Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 3407-3414
[5]
Menard K(2007)Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210-5217
[6]
McGlinchey K(2010)Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 3256-3263
[7]
Peterson RW(2010)Efficacy of ixabepilone in ER/PR/HER2-negative (triple negative) breast cancer Breast Cancer Res Treat 121 261-271
[8]
Lee FY(2009)Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer J Clin Oncol 27 526-534
[9]
Borzilleri R(2007)Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients With metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 3415-3420
[10]
Fairchild CR(2007)Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399-3406